As the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling pathway is responsible for glucose homeostasis, and hyperglycemia is an expected “on-target” side effect because of PI3K inhibition, the most common adverse event in SOLAR-1 was, as expected, hyperglycemia.6,10 The median time to onset of Grade ≥ 3 hyperglycemia in SOLAR-1 was 15 days, which is in the base for the summary of product characteristics guidelines for monitoring and management of alpelisib-induced hyperglycemia. The gene discussed is AKT1; the disease is Hyperglycemia.